『MedTech Global Insights』のカバーアート

MedTech Global Insights

MedTech Global Insights

著者： Ran Chen
無料で聴く

このコンテンツについて

 What's next in the future of health? Welcome to MedTech Global Insights, the podcast dedicated to uncovering the most disruptive technologies and brilliant minds in the medical field. Whether you're an industry professional, investor, or simply curious, subscribe for your dose of cutting-edge information and expert commentary.Copyright 2025 Ran Chen
エピソード
  • From Concept to Clearance: Pure Global's Expert Playbook for Avoiding Common FDA 510(k) Pitfalls

    From Concept to Clearance: Pure Global's Expert Playbook for Avoiding Common FDA 510(k) Pitfalls
    2025/08/25
    Navigating the FDA's 510(k) premarket notification process is a critical hurdle for most Class II medical device manufacturers seeking entry into the lucrative U.S. market. This pathway is designed to demonstrate that a new device is "substantially equivalent" to an existing one, but the journey from submission to clearance is often complex and fraught with challenges that can lead to significant delays and unexpected costs. This episode of MedTech Global Insights unpacks the three most common and costly pitfalls in the 510(k) submission process. We go beyond the basics to provide actionable insights on predicate selection, performance data requirements, and the nuances of crafting a compelling technical narrative for the FDA, including considerations for the new eSTAR format. Case Study: Imagine a MedTech startup pours its resources into a groundbreaking diagnostic device. They rush their 510(k) submission, only to receive a "Refuse to Accept" letter because their performance testing data didn't directly correlate with their chosen predicate device's data. The project is now stalled for months, investor confidence wavers, and their first-mover advantage evaporates. This episode is your guide to preventing that exact scenario. Key Takeaways: * How can selecting the wrong predicate device jeopardize your entire U.S. market strategy? * What specific performance data does the FDA scrutinize most in a substantial equivalence argument? * Why is the "Indications for Use" statement one of the most critical components of your application? * Are you fully prepared for the mandatory FDA eSTAR submission format and its specific requirements? * What are the top three avoidable mistakes that lead to a "Refuse to Accept" (RTA) letter? * How can you leverage AI and data tools to build a stronger, more defensible 510(k) submission? * What level of detail is required in your device description to avoid unnecessary questions from the FDA? For a smarter path to market clearance, contact us at info@pureglobal.com or visit https://pureglobal.com/.
    続きを読む 一部表示
    4 分
  • Cracking the Code of FDA Medical Device Registration: A Pure Global Deep Dive into 510(k) vs. PMA Pathways for US Market Success

    Cracking the Code of FDA Medical Device Registration: A Pure Global Deep Dive into 510(k) vs. PMA Pathways for US Market Success
    2025/08/24
    This episode of MedTech Global Insights delves into the critical process of FDA medical device registration, the essential first step for entering the lucrative U.S. market. We break down the three core regulatory pathways—510(k), Premarket Approval (PMA), and De Novo—and explore the strategic decisions that determine success or failure. Navigating this landscape is fraught with potential missteps. Choosing an incorrect pathway or failing to provide sufficient evidence can result in years of delays and millions in wasted capital, jeopardizing a product's launch. This episode provides the foundational knowledge to help you build a robust and efficient regulatory strategy. A prime example is a medical imaging startup with a novel AI-powered diagnostic software. They pursued a 510(k) assuming their software was similar to existing imaging analysis tools. However, the FDA determined their AI's autonomous decision-making capability represented a new level of risk with no clear predicate, leading to a rejection. This forced a costly and time-consuming pivot to a De Novo submission, a delay that could have been avoided with a more nuanced upfront analysis of the device's novelty and risk profile. Key Takeaways: - What are the critical differences between the 510(k), PMA, and De Novo pathways? - How do you select a "substantially equivalent" predicate device for a 510(k) submission and avoid common pitfalls? - When is the rigorous and data-intensive PMA pathway unavoidable for your device? - For a truly novel technology, how do you determine if the De Novo pathway is the right strategic choice? - What are the most common reasons the FDA rejects submissions? - Beyond the main application, what are the essential administrative duties like establishment registration and device listing? - How can you proactively budget for MDUFA user fees to avoid financial surprises? - Why could a pre-submission meeting with the FDA be the most important meeting you take? For more information, contact us at info@pureglobal.com or visit https://pureglobal.com/
    続きを読む 一部表示
    4 分
  • Unlocking Global Markets for Orthopedic Implants: A Pure Global Guide to Navigating FDA, CE, and Emerging Market Regulations

    Unlocking Global Markets for Orthopedic Implants: A Pure Global Guide to Navigating FDA, CE, and Emerging Market Regulations
    2025/08/23
    In this episode of MedTech Global Insights, we explore the rapidly growing orthopedic implant market and the immense regulatory challenges that manufacturers face. With an aging global population driving demand for devices like knee, hip, and spinal implants, the path to international market access has never been more complex. We break down the specific hurdles in key regions, from the stringent clinical evidence requirements of the EU's MDR to the nuanced 510(k) pathway of the US FDA. We also examine the unique difficulties in emerging markets across Asia and Latin America, where local regulations can create significant delays. This episode provides a strategic roadmap for overcoming these obstacles through an integrated, technology-driven approach. A real-world example. a European scaleup developed an innovative spinal cage. They achieved CE marking but then hit a wall. Their plans to launch in Brazil, South Korea, and Mexico simultaneously were stalled by conflicting requirements, language barriers, and the need to find a separate local representative for each country, delaying their expansion by over 18 months. In this episode, you will learn the answers to these questions: - Why has the EU MDR become the biggest regulatory challenge for orthopedic implant manufacturers? - What are the critical differences in clinical data requirements between the US FDA and European authorities? - How can you leverage a single technical dossier to gain access to over 30 global markets simultaneously? - What are the hidden costs and delays when registering devices in key emerging markets? - How can AI technology dramatically accelerate the compilation and submission of your regulatory documents? - What specific post-market surveillance activities are now mandatory for orthopedic devices in Europe? - How do you select the right international markets for your product to maximize ROI on regulatory spending? Contact us for more information at info@pureglobal.com or visit https://pureglobal.com/
    続きを読む 一部表示
    3 分
まだレビューはありません